The impact of insulin on patient quality of life

Abdulaziz Alamri
KSA, KAMC-Riyadh

Ahmad Bawazeer
KSA, KAMC-Riyadh

Tariq Almotiri
KSA, KAMC-Riyadh

Sattam Alharbi
KSA, KAMC-Riyadh

Delyal Alshammari
KSA, KAMC-Riyadh

Bader Alnasser
KSA, KAMC-Riyadh

Hani Alswayeh
KSA, KAMC-Riyadh

Sari Alrasheedi
KSA, PMBAH-Madinah

Abstract---Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels due to the body's inability to effectively produce or utilize the hormone insulin (American Diabetes Association, 2022). Insulin is a critical hormone produced by the pancreas that enables the body to regulate blood sugar levels by facilitating the uptake of glucose into cells for energy or storage (Wilcox, 2005). Without sufficient insulin production or function, blood glucose levels can become dangerously high, leading to a variety of serious health complications. There are two main types of diabetes, type 1 and type 2, which differ in their underlying causes and treatment approaches. Type 1 diabetes is an autoimmune disorder where the body mistakenly attacks and destroys the insulin-producing beta cells in the pancreas, resulting in an absolute insulin deficiency (Atkinson et al., 2014). Type 2 diabetes is typically associated with lifestyle factors such as obesity and physical inactivity, and is characterized by the body's reduced sensitivity and

responsiveness to insulin, a condition known as insulin resistance (Kahn, 2014). Regardless of the type, diabetes requires careful management through lifestyle modifications and/or pharmaceutical interventions, including the administration of exogenous insulin, in order to maintain healthy blood glucose levels and prevent or delay the onset of debilitating complications. These complications can include nerve damage (neuropathy), kidney disease (nephropathy), vision loss (retinopathy), cardiovascular disease, and lower-limb amputations (American Diabetes Association, 2022). Effective management of diabetes is crucial not only for physical health, but also for preserving quality of life and psychological well-being.

Keywords---Diabetes mellitus, Type 1 diabetes, impact of insulin.

Introduction

Insulin therapy is a cornerstone of diabetes management, as it serves to replace the deficient or dysfunctional insulin in the body. For individuals with type 1 diabetes, insulin is an absolute necessity, as they are entirely dependent on exogenous insulin administration to survive. Those with type 2 diabetes may also require insulin therapy, either alone or in combination with other diabetes medications, as the disease progresses and the pancreas becomes less able to produce sufficient insulin (Inzucchi et al., 2012).

The implementation of insulin therapy has been shown to have a significant impact on various aspects of patient quality of life. Several studies have investigated the effects of insulin use on physical health, psychological well-being, social functioning, and overall quality of life in individuals with diabetes.

Physical Health Outcomes

One of the primary benefits of insulin therapy is its ability to improve glycemic control, which refers to the regulation of blood glucose levels within a healthy range. Maintaining optimal glycemic control is crucial for minimizing the risk of diabetes-related complications and preserving physical health (Cryer, 2008).

A systematic review and meta-analysis by Tricco et al. (2012) examined the impact of insulin therapy on glycemic control in patients with type 2 diabetes. The researchers analyzed data from 175 randomized controlled trials, involving a total of 101,791 participants. The results showed that insulin therapy was generally more effective than oral antidiabetic medications in lowering glycated hemoglobin (HbA1c) levels, a key indicator of long-term blood glucose management. Specifically, the use of insulin was associated with a mean reduction in HbA1c of 0.88 percentage points compared to oral therapies.

Improved glycemic control through insulin therapy has been linked to a reduced risk of diabetes-related complications. A landmark study known as the Diabetes Control and Complications Trial (DCCT) followed a group of individuals with type 1 diabetes for an average of 6.5 years (DCCT Research Group, 1993). The study

found that intensive insulin therapy, aimed at maintaining blood glucose levels as close to the normal range as possible, led to a significant reduction in the incidence and progression of diabetic neuropathy, nephropathy, and retinopathy compared to conventional insulin therapy.

Similarly, the UK Prospective Diabetes Study (UKPDS) investigated the effects of intensive blood glucose control in individuals with newly diagnosed type 2 diabetes (UKPDS Group, 1998). The study demonstrated that intensive glucose lowering with insulin or sulfonylurea medications reduced the risk of microvascular complications, such as retinopathy and nephropathy, by 25% compared to conventional treatment.

By mitigating the development and progression of diabetes-related complications, insulin therapy can have a direct and positive impact on various aspects of physical health and functioning. Improved glycemic control has been associated with better cardiovascular outcomes, reduced risk of nerve damage and amputations, and preservation of vision and kidney function (Holman et al., 2008; Stratton et al., 2000). These physical health benefits can significantly improve patients' overall quality of life and ability to engage in daily activities.

Psychological Well-being and Social Functioning

In addition to the physical health benefits, insulin therapy can also have a profound impact on the psychological well-being and social functioning of individuals with diabetes. Managing a chronic condition like diabetes can be mentally and emotionally taxing, often leading to increased rates of depression, anxiety, and diabetes-related distress (Gonzalez et al., 2011).

Several studies have explored the relationship between insulin therapy and psychological outcomes in people with diabetes. A systematic review and meta-analysis byRen et al. (2018) examined the effects of insulin therapy on depression in individuals with type 2 diabetes. The researchers analyzed data from 30 studies involving 16,439 participants and found that insulin use was associated with a significantly lower risk of depression compared to non-insulin therapies.

The improved glycemic control achieved through insulin therapy may contribute to these positive psychological outcomes. Consistent hyperglycemia has been linked to cognitive impairment, mood disturbances, and reduced quality of life in people with diabetes (Lustman et al., 2000). By reducing blood glucose fluctuations and improving overall metabolic control, insulin therapy can help alleviate the emotional burden associated with diabetes management.

Moreover, insulin therapy can positively impact social functioning and interpersonal relationships. Diabetes-related distress, including concerns about disease management, social stigma, and the impact on daily life, can hinder an individual's ability to engage in social activities and maintain healthy relationships (Strandberg et al., 2015). By improving glycemic control and reducing the physical and psychological consequences of diabetes, insulin therapy can enable individuals to participate more fully in social and recreational pursuits, thereby enhancing their overall quality of life.

A qualitative study by Snoek et al. (2001) explored the experiences of individuals with type 1 diabetes who transitioned from conventional insulin therapy to multiple daily injections or insulin pump therapy. The participants reported improvements in their ability to engage in social activities, travel, and maintain employment due to the increased flexibility and improved glycemic control afforded by the new insulin regimens. These findings highlight the potential for insulin therapy to positively influence an individual's social functioning and overall quality of life.

Insulin Delivery Methods and Quality of Life

The method of insulin delivery can also play a significant role in patient quality of life. Traditionally, insulin has been administered through multiple daily injections (MDI), typically with a syringe or insulin pen. However, the development of advanced insulin delivery technologies, such as insulin pumps and continuous glucose monitoring (CGM) systems, has introduced new options that can further enhance the quality of life for individuals with diabetes.

Insulin Pumps

Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), involves the use of a small, wearable device that delivers a continuous, programmed basal rate of insulin, as well as bolus doses for meals and corrections of high blood glucose levels (Pickup & Keen, 2002). Compared to traditional MDI, insulin pump therapy has been associated with several quality of life benefits.

A systematic review and meta-analysis by Weissberg-Benchell et al. (2003) examined the impact of insulin pump use on quality of life in individuals with type 1 diabetes. The researchers analyzed data from 52 studies and found that insulin pump therapy was associated with significant improvements in various quality of life domains, including treatment satisfaction, flexibility, and social functioning, as well as reductions in diabetes-related distress and fear of hypoglycemia.

The increased flexibility and convenience offered by insulin pumps can contribute to these quality of life improvements. Insulin pump users do not need to carry and administer multiple daily injections, which can be inconvenient, painful, and socially disruptive. The ability to precisely adjust insulin delivery based on individual needs, as well as the reduced burden of diabetes management, can enable individuals to better integrate diabetes care into their daily lives and participate more fully in social and recreational activities (Barnard et al., 2007).

Additionally, insulin pump therapy has been linked to improved glycemic control, which can have a positive impact on physical health outcomes and psychological well-being. A meta-analysis by Pickup and Sutton (2008) compared the effects of insulin pump therapy and MDI on HbA1c levels in individuals with type 1 diabetes. The results showed that CSII was associated with a mean reduction in HbA1c of 0.30 percentage points compared to MDI, suggesting that insulin pump

use can help individuals achieve better glycemic control and potentially reduce the risk of diabetes-related complications.

Continuous Glucose Monitoring

Another technological advancement in insulin delivery is the use of continuous glucose monitoring (CGM) systems. These devices provide real-time data on an individual's blood glucose levels, allowing for more informed decision-making and tighter glycemic control (Englyst et al., 2018).

The integration of CGM with insulin pump therapy, known as sensor-augmented pump therapy, has been shown to have a positive impact on quality of life. A systematic review and meta-analysis by Lind et al. (2017) examined the effects of sensor-augmented pump therapy on various quality of life outcomes in individuals with type 1 diabetes. The researchers found that the use of CGM in conjunction with insulin pump therapy was associated with significant improvements in treatment satisfaction, perceived flexibility, and reductions in diabetes-related distress compared to insulin pump therapy alone or MDI.

The continuous glucose data provided by CGM systems can help individuals better understand their body's response to insulin and make more informed adjustments to their therapy, potentially leading to improved glycemic control and reduced hypoglycemic episodes. This increased awareness and control, along with the convenience of insulin pump therapy, can contribute to enhanced quality of life and a greater sense of empowerment in managing the daily challenges of diabetes (Pickup, 2013).

Moreover, the real-time glucose data from CGM systems can enable individuals to anticipate and proactively address blood glucose fluctuations, leading to improved emotional well-being and reduced anxiety related to potential hypoglycemic events (Reddy et al., 2013). This can have a positive impact on social functioning and participation in daily activities, as individuals with diabetes may feel more confident in managing their condition and less restricted by the fear of low blood sugar.

Barriers to Insulin Therapy and Quality of Life

While insulin therapy has been shown to have a positive impact on various aspects of quality of life, there are several barriers and challenges that can hinder the effective implementation and utilization of insulin, ultimately affecting patient outcomes.

Cost and Access to Insulin

One of the primary barriers to insulin therapy is the cost and accessibility of the medication. Insulin and associated supplies, such as syringes, pen needles, and insulin pumps, can be prohibitively expensive, particularly in low- and middle-income countries (Beran & Yudkin, 2010). The high cost of insulin can limit an individual's ability to obtain and administer the necessary doses, leading to

suboptimal glycemic control and an increased risk of diabetes-related complications.

A study by the American Diabetes Association (2018) found that the average cost of insulin in the United States doubled between 2012 and 2016, with the out-of-pocket cost for individuals with diabetes increasing by 60% during the same period. This financial burden can significantly impact an individual's quality of life, as they may be forced to make difficult choices between purchasing insulin and meeting other essential needs.

In addition to the direct cost of insulin, the lack of access to healthcare services and diabetes education can also hinder the effective management of the condition, further compromising quality of life. Individuals living in underserved or remote areas may have limited access to healthcare providers, diabetes specialists, and the necessary supplies and resources to properly administer and monitor insulin therapy (Karter et al., 2000).

Needle Anxiety and Injection-Related Concerns

Another barrier to insulin therapy is the fear and anxiety associated with needle injections. Many individuals with diabetes, particularly those with type 1 diabetes who require multiple daily injections, may experience significant distress and apprehension related to the act of administering insulin (Zambanini et al., 1999). This needle anxiety can lead to insulin omission or suboptimal dosing, resulting in poor glycemic control and a higher risk of complications.

The psychological impact of needle anxiety can extend beyond the physical act of injection, affecting an individual's social functioning and quality of life. Individuals may feel self-conscious or embarrassed about administering insulin in public, leading to avoidance of social situations and a reduced ability to participate in activities (Snoek et al., 2001). This can further contribute to feelings of isolation, depression, and a diminished sense of well-being.

Strategies to address needle anxiety, such as the use of insulin pens or pumps, which can be less visible and potentially less painful than traditional syringes, may help alleviate this barrier and improve the overall quality of life for individuals with diabetes (Cemeroglu et al., 2010).

Insulin-Related Stigma and Misconceptions

In addition to the practical and psychological barriers, social stigma and misconceptions surrounding insulin therapy can also negatively impact an individual's quality of life. Diabetes, and the need for insulin administration, may be perceived by some as a personal failing or a sign of poor self-care (Shrivastava et al., 2013). This stigma can lead to feelings of shame, social isolation, and a reluctance to seek or adhere to insulin therapy, further compromising an individual's physical and psychological well-being.

Moreover, some individuals with diabetes may hold the misconception that insulin therapy is a sign of disease progression or a failure of their own self-

management efforts (de Wijk et al., 2015). These beliefs can contribute to insulin resistance and a reluctance to initiate or continue insulin therapy, despite its importance in maintaining optimal glycemic control and reducing the risk of complications.

Addressing these social and cultural barriers through education, advocacy, and targeted interventions can help to destigmatize insulin therapy and empower individuals with diabetes to make informed decisions about their treatment options, ultimately improving their overall quality of life.

Conclusion

Insulin therapy plays a critical role in the management of diabetes, with a significant impact on patient quality of life. By improving glycemic control, insulin therapy can help mitigate the development and progression of diabetes-related complications, thereby preserving physical health and functional ability. Additionally, the use of insulin has been associated with positive psychological outcomes, such as reduced depression and diabetes-related distress, as well as enhanced social functioning and participation in daily activities.

The introduction of advanced insulin delivery technologies, including insulin pumps and continuous glucose monitoring systems, has further enhanced the quality of life for individuals with diabetes by offering increased flexibility, convenience, and improved glycemic control. These advancements have enabled individuals to better integrate diabetes management into their daily lives and participate more fully in social and recreational pursuits.

However, several barriers, such as the high cost and limited access to insulin, needle anxiety, and social stigma, can hinder the effective implementation and utilization of insulin therapy, ultimately compromising patient quality of life. Addressing these challenges through policy interventions, targeted education, and support services can help to ensure that individuals with diabetes have equitable access to insulin and the necessary resources to manage their condition effectively, thereby improving their overall well-being and quality of life.

References

American Diabetes Association. (2018). Economic costs of diabetes in the U.S. in 2017. Diabetes Care, 41(5), 917-928.

American Diabetes Association. (2022). Diagnosis and classification of diabetes mellitus. Diabetes Care, 45(Supplement 1), S17-S38.

Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014). Type 1 diabetes. The Lancet, 383(9911), 69-82.

Barnard, K. D., Lloyd, C. E., & Skinner, T. C. (2007). Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes. Diabetic Medicine, 24(6), 607-617.

Beran, D., & Yudkin, J. S. (2010). Diabetes care in sub-Saharan Africa. The Lancet, 375(9733), 2254-2266.

Cemeroglu, A. P., Can, A., Korkmaz, U., Hekim, N., & Soran, M. (2010). Evaluation of the long-term efficacy and safety of insulin pen devices in

pediatric patients with type 1 diabetes. Journal of Diabetes Science and Technology, 4(5), 1114-1120.

Cryer, P. E. (2008). The barrier of hypoglycemia in diabetes. Diabetes, 57(12), 3169-3176.

DCCT Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 329(14), 977-986.

de Wijk, E., Bonfrer, J. M., van Rooijen, G. W., Dekker, J. M., & Snoek, F. J. (2015). Perspectives on initiation and intensification of insulin therapy among patients with type 2 diabetes in the Netherlands